BeiGene Corporate Overview

Beigene is a global oncology company that was built differently to deliver innovative medicines faster, more equitably and affordably around the world.

Our founding belief is that there is a better way to bring innovative treatments to patients around the world. We are an oncology powerhouse with a deep, diverse pipeline fueled by one of the industry's largest and most productive research teams.

Our two foundational medicines, BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab), demonstrate the strength of our science and our mission to improve treatment outcomes for patients.

Today, **more than 10,000** colleagues operate in more than **40 markets** across **five continents**. **More than 1 million** patients have been treated with our medicines, reflecting our expansive global reach and deep commitment to access.

Facts at a Glance

10k+
Colleagues globally in over **40** offices on **5** continents

$2.5B
Annual product revenue
$3.2B cash balance*

1.3M+
Patients treated with our medicines

30+
Assets in clinical and commercial stages

3.7k+
Global commercial team members

In-house manufacturing
including U.S. expansion

1.1k+
Oncology research team

40+
Phase 3 or potentially registration enabling trials

~20
Industry collaborations

*As of February 26, 2024

For more information visit:

BeiGene.com | @BeiGeneGlobal | Linkedin.com/Company/BeiGene | BeiGene Global | @BeiGeneGlobal

BeiGene

Innovative Science Responding to the Greatest Areas of Need

We have one of the largest and most productive oncology research teams in the world, with **more than 1,100 highly-credentialed scientists** with a proven track record of developing innovative medicines that address significant unmet needs. We also have **one of the largest and most compelling oncology pipelines** in the industry covering 80% of the world's cancers by incidence.

50+
Preclinical programs ongoing

16
Internally discovered molecules in clinical development as of 2023

40+
Phase 3 or potentially registration enabling trials

10+
New molecules entering the clinic expected each year from 2024

3
Internally developed cancer medicines approved

Global Capabilities to Reach More Patients

We are challenging industry conventions with our own in-house drug discovery and development capabilities. In just over a decade, this model has generated one of the industry's most robust oncology pipelines, conducted **more than 130 clinical trials** among **more than 20,000 patients,** and received regulatory approvals in **more than 70 markets** across three internally developed medicines.

Our fully integrated manufacturing capabilities also allow us to speed-up our clinical development efforts while ensuring the highest-quality production of our clinical and commercial portfolio of small-molecule, biologics and emerging modality therapeutics.

Our Princeton West Innovation Campus in New Jersey houses a state-of-the art, clinical andcommercial-stage biologics manufacturing facility and clinical R&D center, which complement our existing capabilities around the world.

For more information visit:

BeiGene.com | @BeiGeneGlobal | Linkedin.com/Company/BeiGene | BeiGene Global | @BeiGeneGlobal

BeiGene